From Barrett metaplasia to esophageal adenocarcinoma: The molecular background

Histology and Histopathology

Volumn 31, Issue 1, 2016, Pages 25-32

  Saraggi, Deborah ^a   Fassan, Matteo ^a   Bornschein, Jan ^b,c   Farinati, Fabio ^a   Realdon, Stefano ^d   Valeri, Nicola ^e   Rugge, Massimo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Barrett s esophagus; Biomarker; MicroRNA; Molecular pathology

Indexed keywords

TUMOR MARKER; TUMOR PROTEIN;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGUS TUMOR; GENETICS; HUMAN; METABOLISM; PATHOLOGY;

ADENOCARCINOMA; BARRETT ESOPHAGUS; BIOMARKERS, TUMOR; ESOPHAGEAL NEOPLASMS; HUMANS; NEOPLASM PROTEINS;

EID: 84949057541     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: 10.14670/HH-11-659     Document Type: Review

References (82)

1. Anaparthy R. and Sharma P. (2014). Progression of Barrett oesophagus: role of endoscopic and histological predictors. Nat. Rev. Gastroenterol. Hepatol. 11, 525-534.
2. Bang Y. J., Van Cutsem E., Feyereislova A., Chung H. C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., Aprile G., Kulikov E., Hill J., Lehle M., Ruschoff J., Kang Y. K. and ToGA Trial Investigators (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376, 687-697.
3. Bansal A., Lee I. H., Hong X., Anand V., Mathur S. C., Gaddam S., Rastogi A., Wani S. B., Gupta N., Visvanathan M., Sharma P. and Christenson L. K. (2011). Feasibility of mcroRNAs as biomarkers for Barrett's Esophagus progression: a pilot cross-sectional, phase 2 biomarker study. Am. J. Gastroenterol. 106, 1055-1063.
4. Bian Y. S., Osterheld M. C., Bosman F. T., Benhattar J. and Fontolliet C. (2001). p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Mod. Pathol. 14, 397-403.
5. Bian Y. S., Osterheld M. C., Fontolliet C., Bosman F. T. and Benhattar J. (2002). p16 inactivation by methylation of the CDKN2A promoter occurs early during neoplastic progression in Barrett's esophagus. Gastroenterology 122, 1113-1121.
6. Calin G. A., Liu C. G., Ferracin M., Hyslop T., Spizzo R., Sevignani C., Fabbri M., Cimmino A., Lee E. J., Wojcik S. E., Shimizu M., Tili E., Rossi S., Taccioli C., Pichiorri F., Liu X., Zupo S., Herlea V., Gramantieri L., Lanza G., Alder H., Rassenti L., Volinia S., Schmittgen T. D., Kipps T. J., Negrini M. and Croce C. M. (2007). Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell. 12, 215-229.
7. Clemons N. J., Koh S. Y. and Phillips W. A. (2014). Advances in understanding the pathogenesis of Barrett's esophagus. Discov. Med. 17, 7-14.
8. Cronin J., McAdam E., Danikas A., Tselepis C., Griffiths P., Baxter J., Thomas L., Manson J. and Jenkins G. (2011). Epidermal growth factor receptor (EGFR) is overexpressed in high-grade dysplasia and adenocarcinoma of the esophagus and may represent a biomarker of histological progression in Barrett's esophagus (BE). Am. J. Gastroenterol. 106, 46-56.
9. Dall'Olmo L., Fassan M., Dassie E., Scarpa M., Realdon S., Cavallin F., Cagol M., Battaglia G., Pizzi M., Guzzardo V., Franceschinis E., Pasut G., Rugge M., Zaninotto G., Realdon N. and Castoro C. (2014). Role of proton pump inhibitor on esophageal carcinogenesis and pancreatic acinar cell metaplasia development: an experimental in vivo study. PLoS One 9, e112862.
10. D'Angelo E., Vicentini C., Agostini M., Kiss A., Baffa R., Scarpa A. and Fassan M. (2015). MicroRNAs as Tools and Effectors for Patient Treatment in Gastrointestinal Carcinogenesis. Curr. Drug Targets 16, 383-392.
11. Di Leva G., Garofalo M. and Croce C. M. (2014). MicroRNAs in cancer. Annu. Rev. Pathol. 9, 287-314.
12. di Pietro M., Lao-Sirieix P., Boyle S., Cassidy A., Castillo D., Saadi A., Eskeland R. and Fitzgerald R. C. (2012). Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus. Proc. Natl. Acad. Sci. USA 109, 9077-9082.
13. Dvorak K., Payne C. M., Chavarria M., Ramsey L., Dvorakova B., Bernstein H., Holubec H., Sampliner R. E., Guy N., Condon A., Bernstein C., Green S. B., Prasad A. and Garewal H. S. (2007). Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett's oesophagus. Gut 56, 763-771.
14. Dvorakova K., Payne C. M., Ramsey L., Holubec H., Sampliner R., Dominguez J., Dvorak B., Bernstein H., Bernstein C., Prasad A., Fass R., Cui H. and Garewal H. (2004). Increased expression and secretion of interleukin-6 in patients with Barrett's esophagus. Clin. Cancer Res. 10, 2020-2028.
15. Esteller M. (2011). Non-coding RNAs in human disease. Nat. Rev. Genet. 12, 861-874.
16. Fassan M., Pizzi M., Battaglia G., Giacomelli L., Parente P., Bocus P., Ancona E. and Rugge M. (2010). Programmed cell death 4 (PDCD4) expression during multistep Barrett's carcinogenesis. J. Clin. Pathol. 63, 692-696.
17. Fassan M., Croce C. M. and Rugge M. (2011a). miRNAs in precancerous lesions of the gastrointestinal tract. World J. Gastroenterol. 17, 5231-5239.
18. Fassan M., Volinia S., Palatini J., Pizzi M., Baffa R., De Bernard M., Battaglia G., Parente P., Croce C. M., Zaninotto G., Ancona E. and Rugge M. (2011b). MicroRNA expression profiling in human Barrett's carcinogenesis. Int. J. Cancer 129, 1661-1670.
19. Fassan M., Ludwig K., Pizzi M., Castoro C., Guzzardo V., Balistreri M., Zaninotto G., Ruol A., Giacomelli L., Ancona E. and Rugge M. (2012a). Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Hum. Pathol. 43, 1206-1212.
20. Fassan M., Mastracci L., Grillo F., Zagonel V., Bruno S., Battaglia G., Pitto F., Nitti D., Celiento T., Zaninotto G., Fiocca R. and Rugge M. (2012b). Early HER2 dysregulation in gastric and oesophageal carcinogenesis. Histopathology 61, 769-776.
21. Fassan M. and Baffa R. (2013). MicroRNAs and targeted therapy: small molecules of unlimited potentials. Curr. Opin. Genet. Dev. 23, 75-77.
22. Fassan M., Baffa R. and Kiss A. (2013a). Advanced precancerous lesions within the GI tract: the molecular background. Best Pract. Res. Clin. Gastroenterol. 27, 159-169.
23. Fassan M., Pizzi M., Realdon S., Balistreri M., Guzzardo V., Zagonel V., Castoro C., Mastracci L., Farinati F., Nitti D., Zaninotto G. and Rugge M. (2013b). The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis. Hum. Pathol. 44, 1804-1810.
24. Fassan M., Volinia S., Palatini J., Pizzi M., Fernandez-Cymering C., Balistreri M., Realdon S., Battaglia G., Souza R., Odze R. D., Zaninotto G., Croce C. M. and Rugge Md Facg M. (2013c). MicroRNA Expression Profiling in the Histological Subtypes of Barrett's Metaplasia. Clin. Transl. Gastroenterol. 4, e34.
25. Fassan M., Dall'Olmo L., Galasso M., Braconi C., Pizzi M., Realdon S., Volinia S., Valeri N., Gasparini P., Baffa R., Souza R. F., Vicentini C., D'Angelo E., Bornschein J., Nuovo G. J., Zaninotto G., Croce C. M. and Rugge M. (2014a). Transcribed ultraconserved noncoding RNAs (T-UCR) are involved in Barrett's esophagus carcinogenesis. Oncotarget 5, 7162-7171.
26. Fassan M., Simbolo M., Bria E., Mafficini A., Pilotto S., Capelli P., Bencivenga M., Pecori S., Luchini C., Neves D., Turri G., Vicentini C., Montagna L., Tomezzoli A., Tortora G., Chilosi M., De Manzoni G. and Scarpa A. (2014b). High-throughput mutation profiling identifies novel molecular dysregulation in high-grade intraepithelial neoplasia and early gastric cancers. Gastric Cancer 17, 442-449.
27. Feber A., Xi L., Luketich J. D., Pennathur A., Landreneau R. J., Wu M., Swanson S. J., Godfrey T. E. and Litle V. R. (2008). MicroRNA expression profiles of esophageal cancer. J. Thorac. Cardiovasc. Surg. 135, 255-60; discussion 260.
28. Fiocca R., Mastracci L., Milione M., Parente P., Savarino V., Gruppo Italiano Patologi Apparato Digerente (GIPAD) and Societa Italiana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology, Italian division (SIAPEC/IAP) (2011). Microscopic esophagitis and Barrett's esophagus: the histology report. Dig. Liver Dis. 43 (Suppl 4), S319-30.
29. Fitzgerald R. C., di Pietro M., Ragunath K., Ang Y., Kang J. Y., Watson P., Trudgill N., Patel P., Kaye P. V., Sanders S., O'Donovan M., Bird-Lieberman E., Bhandari P., Jankowski J. A., Attwood S., Parsons S. L., Loft D., Lagergren J., Moayyedi P., Lyratzopoulos G., de Caestecker J. and British Society of Gastroenterology (2014). British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut 63, 7-42.
30. Gao N., White P. and Kaestner K. H. (2009). Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdx2. Dev. Cell. 16, 588-599.
31. Genta R. M. and Rugge M. (1999). Gastric precancerous lesions: heading for an international consensus. Gut 45 (Suppl 1), I5-8.
32. Gibson M. K., Dhaliwal A. S., Clemons N. J., Phillips W. A., Dvorak K., Tong D., Law S., Pirchi E. D., Rasanen J., Krasna M. J., Parikh K., Krishnadath K. K., Chen Y., Griffiths L., Colleypriest B. J., Farrant J. M., Tosh D., Das K. M. and Bajpai M. (2013). Barrett's esophagus: cancer and molecular biology. Ann. NY Acad. Sci. 1300, 296-314.
33. Grillo F., Fassan M., Ceccaroli C., Giacometti C., Curto M., Zagonel V., Ceppa P., Nitti D., Castoro C., Fiocca R., Rugge M. and Mastracci L. (2013). The Reliability of Endoscopic Biopsies in Assessing HER2 Status in Gastric and Gastroesophageal Junction Cancer: A Study Comparing Biopsies with Surgical Samples. Transl. Oncol. 6, 10-16.
34. Groisman G. M., Amar M. and Meir A. (2004). Expression of the intestinal marker Cdx2 in the columnar-lined esophagus with and without intestinal (Barrett's) metaplasia. Mod. Pathol. 17, 1282-1288.
35. Huo X., Zhang H. Y., Zhang X. I., Lynch J. P., Strauch E. D., Wang J. Y., Melton S. D., Genta R. M., Wang D. H., Spechler S. J. and Souza R. F. (2010). Acid and bile salt-induced CDX2 expression differs in esophageal squamous cells from patients with and without Barrett's esophagus. Gastroenterology 139, 194-203. e1.
36. Ingravallo G., Dall'Olmo L., Segat D., Fassan M., Mescoli C., Dazzo E., Castoro C., Polimeno L., Rizzetto C., Baroni M. D., Zaninotto G., Ancona E. and Rugge M. (2009). CDX2 hox gene product in a rat model of esophageal cancer. J. Exp. Clin. Cancer Res. 28, 108-9966-28-108.
37. Jin Z., Cheng Y., Gu W., Zheng Y., Sato F., Mori Y., Olaru A. V., Paun B. C., Yang J., Kan T., Ito T., Hamilton J. P., Selaru F. M., Agarwal R., David S., Abraham J. M., Wolfsen H. C., Wallace M. B., Shaheen N. J., Washington K., Wang J., Canto M. I., Bhattacharyya A., Nelson M. A., Wagner P. D., Romero Y., Wang K. K., Feng Z., Sampliner R. E. and Meltzer S. J. (2009). A multicenter, double-blinded validation study of methylation biomarkers for progression prediction in Barrett's esophagus. Cancer Res. 69, 4112-4115.
38. Kan T. and Meltzer S. J. (2009). MicroRNAs in Barrett's esophagus and esophageal adenocarcinoma. Curr. Opin. Pharmacol. 9, 727-732.
39. Kan T., Sato F., Ito T., Matsumura N., David S., Cheng Y., Agarwal R., Paun B. C., Jin Z., Olaru A. V., Selaru F. M., Hamilton J. P., Yang J., Abraham J. M., Mori Y. and Meltzer S. J. (2009). The miR-106b-25 polycistron, activated by genomic amplification, functions as an oncogene by suppressing p21 and Bim. Gastroenterology 136, 1689-1700.
40. Kazumori H., Ishihara S., Rumi M. A., Kadowaki Y. and Kinoshita Y. (2006). Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett's epithelium. Gut 55, 16-25.
41. Lao-Sirieix P. and Fitzgerald R. C. (2010). Role of the micro-environment in Barrett's carcinogenesis. Biochem. Soc. Trans. 38, 327-330.
42. Leidner R. S., Ravi L., Leahy P., Chen Y., Bednarchik B., Streppel M., Canto M., Wang J. S., Maitra A., Willis J., Markowitz S. D., Barnholtz-Sloan J., Adams M. D., Chak A. and Guda K. (2012). The microRNAs, MiR-31 and MiR-375, as candidate markers in Barrett's esophageal carcinogenesis. Genes Chromosomes Cancer 51, 473-479.
43. Luchini C., Capelli P., Fassan M., Simbolo M., Mafficini A., Pedica F., Ruzzenente A., Guglielmi A., Corbo V. and Scarpa A. (2014). Nextgeneration histopathologic diagnosis: a lesson from a hepatic carcinosarcoma. J. Clin. Oncol. 32, e63-6.
44. Luthra R., Singh R. R., Luthra M. G., Li Y. X., Hannah C., Romans A. M., Barkoh B. A., Chen S. S., Ensor J., Maru D. M., Broaddus R. R., Rashid A. and Albarracin C. T. (2008). MicroRNA-196a targets annexin A1: a microRNA-mediated mechanism of annexin A1 downregulation in cancers. Oncogene 27, 6667-6678.
45. Mantovani A. (2010). Molecular pathways linking inflammation and cancer. Curr. Mol. Med. 10, 369-373.
46. Maru D. M., Singh R. R., Hannah C., Albarracin C. T., Li Y. X., Abraham R., Romans A. M., Yao H., Luthra M. G., Anandasabapathy S., Swisher S. G., Hofstetter W. L., Rashid A. and Luthra R. (2009). MicroRNA-196a is a potential marker of progression during Barrett's metaplasia-dysplasia-invasive adenocarcinoma sequence in esophagus. Am. J. Pathol. 174, 1940-1948.
47. Mendelson J., Song S., Li Y., Maru D. M., Mishra B., Davila M., Hofstetter W. L. and Mishra L. (2011). Dysfunctional transforming growth factor-beta signaling with constitutively active Notch signaling in Barrett's esophageal adenocarcinoma. Cancer 117, 3691-3702.
48. Milano F., van Baal J. W., Buttar N. S., Rygiel A. M., de Kort F., DeMars C. J., Rosmolen W. D., Bergman J. J., VAn Marle J., Wang K. K., Peppelenbosch M. P. and Krishnadath K. K. (2007). Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 132, 2412-2421.
49. Moyes L. H., McEwan H., Radulescu S., Pawlikowski J., Lamm C. G., Nixon C., Sansom O. J., Going J. J., Fullarton G. M. and Adams P. D. (2012). Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus. J. Pathol. 228, 99-112.
50. Nancarrow D. J., Handoko H. Y., Smithers B. M., Gotley D. C., Drew P. A., Watson D. I., Clouston A. D., Hayward N. K. and Whiteman D. C. (2008). Genome-wide copy number analysis in esophageal adenocarcinoma using high-density single-nucleotide polymorphism arrays. Cancer Res. 68, 4163-4172.
51. Onwuegbusi B. A., Aitchison A., Chin S. F., Kranjac T., Mills I., Huang Y., Lao-Sirieix P., Caldas C. and Fitzgerald R. C. (2006). Impaired transforming growth factor beta signalling in Barrett's carcinogenesis due to frequent SMAD4 inactivation. Gut 55, 764-774.
52. O'Riordan J. M., Abdel-latif M. M., Ravi N., McNamara D., Byrne P. J., McDonald G. S., Keeling P. W., Kelleher D. and Reynolds J. V. (2005). Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasiaadenocarcinoma sequence in the esophagus. Am. J. Gastroenterol. 100, 1257-1264.
53. Parenti A. R., Rugge M., Frizzera E., Ruol A., Noventa F., Ancona E. and Ninfo V. (1995). P53 Overexpression in the Multistep Process of Esophageal Carcinogenesis. Am. J. Surg. Pathol. 19, 1418-1422.
54. Paulson T. G., Maley C. C., Li X., Li H., Sanchez C. A., Chao D. L., Odze R. D., Vaughan T. L., Blount P. L. and Reid B. J. (2009). Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma. Clin. Cancer Res. 15, 3305-3314.
55. Quante M., Bhagat G., Abrams J. A., Marache F., Good P., Lee M. D., Lee Y., Friedman R., Asfaha S., Dubeykovskaya Z., Mahmood U., Figueiredo J. L., Kitajewski J., Shawber C., Lightdale C. J., Rustgi A. K. and Wang T. C. (2012). Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell. 21, 36-51.
56. Reid B. J. (2001). p53 and neoplastic progression in Barrett's esophagus. Am. J. Gastroenterol. 96, 1321-1323.
57. Reid B. J., Prevo L. J., Galipeau P. C., Sanchez C. A., Longton G., Levine D. S., Blount P. L. and Rabinovitch P. S. (2001). Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am. J. Gastroenterol. 96, 2839-2848.
58. Revilla-Nuin B., Parrilla P., Lozano J. J., de Haro L. F., Ortiz A., Martinez C., Munitiz V., de Angulo D. R., Bermejo J., Molina J., Cayuela M. L. and Yelamos J. (2013). Predictive value of MicroRNAs in the progression of barrett esophagus to adenocarcinoma in a long-term follow-up study. Ann. Surg. 257, 886-893.
59. Rugge M., Correa P., Dixon M. F., Hattori T., Leandro G., Lewin K., Riddell R. H., Sipponen P. and Watanabe H. (2000). Gastric dysplasia: the Padova international classification. Am. J. Surg. Pathol. 24, 167-176.
60. Rugge M., Fassan M., Cavallin F. and Zaninotto G. (2012a). Re: Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J. Natl. Cancer Inst. 104, 1771-1772.
61. Rugge M., Zaninotto G., Parente P., Zanatta L., Cavallin F., Germana B., Macri E., Galliani E., Iuzzolino P., Ferrara F., Marin R., Nisi E., Iaderosa G., Deboni M., Bellumat A., Valiante F., Florea G., Della Libera D., Benini M., Bortesi L., Meggio A., Zorzi M. G., Depretis G., Miori G., Morelli L., Cataudella G., d'Amore E. S., Franceschetti I., Bozzola L., Paternello E., Antonini C., Di Mario F., Dal Bo N., Furlanetto A., Norberto L., Polese L., Iommarini S., Farinati F., Battaglia G., Diamantis G., Realdon S., Guido E., Mastropaolo G., Canova D., Guerini A., Franceschi M. and Zirillo M. (2012b). Barrett's esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA). Ann. Surg. 256, 788-94; discussion 794-5.
62. Rugge M., Pizzi M. and Castoro C. (2015). Definition of Barrett's esophagus dysplasia: are we speaking the same language? World J. Surg. 39, 559-565.
63. Rustgi A. K. and El-Serag H. B. (2014). Esophageal carcinoma. N. Engl. J. Med. 371, 2499-2509.
64. Rygiel A. M., van Baal J. W., Milano F., Wang K. K., ten Kate F. J., Fockens P., Rosmolen W. D., Bergman J. J., Peppelenbosch M. P. and Krishnadath K. K. (2007). Efficient automated assessment of genetic abnormalities detected by fluorescence in situ hybridization on brush cytology in a Barrett esophagus surveillance population. Cancer 109, 1980-1988.
65. Saad R., Chen Z., Zhu S., Jia P., Zhao Z., Washington M. K., Belkhiri A. and El-Rifai W. (2013). Deciphering the unique microRNA signature in human esophageal adenocarcinoma. PLoS One 8, e64463.
66. Schulmann K., Sterian A., Berki A., Yin J., Sato F., Xu Y., Olaru A., Wang S., Mori Y., Deacu E., Hamilton J., Kan T., Krasna M. J., Beer D. G., Pepe M. S., Abraham J. M., Feng Z., Schmiegel W., Greenwald B. D. and Meltzer S. J. (2005). Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk. Oncogene 24, 4138-4148.
67. Shi X. Y., Bhagwandeen B. and Leong A. S. (2008). p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus. Appl. Immunohistochem. Mol. Morphol. 16, 447-452.
68. Silberg D. G., Swain G. P., Suh E. R. and Traber P. G. (2000). Cdx1 and cdx2 expression during intestinal development. Gastroenterology 119, 961-971.
69. Souza R. F., Krishnan K. and Spechler S. J. (2008). Acid, bile, and CDX: the ABCs of making Barrett's metaplasia. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G211-8.
70. Spechler S. J. and Souza R. F. (2014). Barrett's esophagus. N. Engl. J. Med. 371, 836-845.
71. Tamagawa Y., Ishimura N., Uno G., Yuki T., Kazumori H., Ishihara S., Amano Y. and Kinoshita Y. (2012). Notch signaling pathway and Cdx2 expression in the development of Barrett's esophagus. Lab. Invest. 92, 896-909.
72. Tselepis C., Perry I., Dawson C., Hardy R., Darnton S. J., McConkey C., Stuart R. C., Wright N., Harrison R. and Jankowski J. A. (2002). Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 21, 6071-6081.
73. Vallbohmer D., DeMeester S. R., Peters J. H., Oh D. S., Kuramochi H., Shimizu D., Hagen J. A., Danenberg K. D., Danenberg P. V., DeMeester T. R. and Chandrasoma P. T. (2006). Cdx-2 expression in squamous and metaplastic columnar epithelia of the esophagus. Dis. Esophagus 19, 260-266.
74. van Baal J. W., Verbeek R. E., Bus P., Fassan M., Souza R. F., Rugge M., ten Kate F. J., Vleggaar F. P. and Siersema P. D. (2013). microRNA-145 in Barrett's oesophagus: regulating BMP4 signalling via GATA6. Gut 62, 664-675.
75. Wang D. H., Clemons N. J., Miyashita T., Dupuy A. J., Zhang W., Szczepny A., Corcoran-Schwartz I. M., Wilburn D. L., Montgomery E. A., Wang J. S., Jenkins N. A., Copeland N. A., Harmon J. W., Phillips W. A. and Watkins D. N. (2010). Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology 138, 1810-1822.
76. Wang J. S., Guo M., Montgomery E. A., Thompson R. E., Cosby H., Hicks L., Wang S., Herman J. G. and Canto M. I. (2009). DNA promoter hypermethylation of p16 and APC predicts neoplastic progression in Barrett's esophagus. Am. J. Gastroenterol. 104, 2153-2160.
77. Weaver J. M., Ross-Innes C. S., Shannon N., Lynch A. G., Forshew T., Barbera M., Murtaza M., Ong C. A., Lao-Sirieix P., Dunning M. J., Smith L., Smith M. L., Anderson C. L., Carvalho B., O'Donovan M., Underwood T. J., May A. P., Grehan N., Hardwick R., Davies J., Oloumi A., Aparicio S., Caldas C., Eldridge M. D., Edwards P. A., Rosenfeld N., Tavare S., Fitzgerald R. C. and OCCAMS Consortium (2014). Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat. Genet. 46, 837-843.
78. Wijnhoven B. P., Hussey D. J., Watson D. I., Tsykin A., Smith C. M., Michael M. Z. and South Australian Oesophageal Research Group (2010). MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. Br. J. Surg. 97, 853-861.
79. Wu X., Ajani J. A., Gu J., Chang D. W., Tan W., Hildebrandt M. A., Huang M., Wang K. K. and Hawk E. (2013). MicroRNA expression signatures during malignant progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer Prev. Res. (Phila) 6, 196-205.
80. Yamanaka Y., Shiotani A., Fujimura Y., Ishii M., Fujita M., Matsumoto H., Tarumi K., Kamada T., Hata J. and Haruma K. (2011). Expression of Sonic hedgehog (SHH) and CDX2 in the columnar epithelium of the lower oesophagus. Dig. Liver Dis. 43, 54-59.
81. Yang H., Gu J., Wang K. K., Zhang W., Xing J., Chen Z., Ajani J. A. and Wu X. (2009). MicroRNA expression signatures in Barrett's esophagus and esophageal adenocarcinoma. Clin. Cancer Res. 15, 5744-5752.
82. Zhang X., Yu C., Wilson K., Zhang H. Y., Melton S. D., Huo X., Wang D. H., Genta R. M., Spechler S. J. and Souza R. F. (2010). Malignant transformation of non-neoplastic Barrett's epithelial cells through well-defined genetic manipulations. PLoS One 5, e13093.